Kolon TissueGene, Inc. (KOSDAQ: 950160) develops cell and gene therapies for orthopedic diseases and degenerative disorders including osteoarthritis of the knee, hip, and spine; rheumatoid arthritis; meniscus injuries; spinal disc disease; and nerve regeneration. The company offers core pipeline products comprising TG-C (Invossa), a genetically engineered allogeneic cell therapy in Phase 3 trials in the U.S. for knee osteoarthritis involving over 1,000 patients with topline results expected mid-2026; TG-B for bone regeneration; TG-D for disc regeneration; and TG-N for nerve regeneration; alongside applications in musculoskeletal disorders and veterinary medicine for knee osteoarthritis. Founded in 1999 and headquartered in Rockville, Maryland, USA, Kolon TissueGene conducts operations primarily in the United States with a focus on major markets such as the U.S., Europe, and Japan, supported by affiliates including Kolon Life Science and Kolon Biotech for integrated R&D, production, and clinical development. In recent developments, the company completed Phase 3 patient dosing for TG-C in July 2024, presented long-term safety data and potential U.S. FDA pathways at the OARSI World Congress in April 2025, participated in BIO International Convention and BIO US 2025 to pursue commercialization strategies including partnerships with Big Pharma and specialty firms, and advanced construction of TG-C-specific production facilities as of early 2025 while exploring market expansion amid positive analyst outlooks for Phase 3 success in July 2026. Kolon TissueGene, formerly TissueGene, Inc., changed its name in March 2018 and employs approximately 29 people under President and CEO Moon Jong Noh.